Ads
related to: squamous cell carcinoma treatmentcancer.osu.edu has been visited by 10K+ users in the past month
- Find a Location
Get Directions To The James
Locations in Central Ohio
- Find A Doctor
Browse The James Top Doctor By
Specialty, Cancer Type or Name
- The CARE Clinic
Cancer And Aging Resiliency Clinic
Serves older adults with cancer
- Follow the Blog
Get The Latest News
And Updates from The James
- Patient Support
Access to Information, Resource &
Activities Available to Support You
- New Diagnostic Center
Same or Next Day Access to
Cancer Diagnostic Experts
- Find a Location
Search results
How age affects laryngeal cancer rates, treatment, and more
Medical News Today· 4 days agoLaryngeal cancer is more common in older adults than in younger people. Laryngeal cancer is much...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 2 days ago(Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the ...
Purple Biotech (NASDAQ:PPBT) Receives Buy Rating from HC Wainwright
ETF DAILY NEWS· 3 days agoPurple Biotech (NASDAQ:PPBT – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently ...
Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research...
Benzinga· 2 days ago49 scheduled presentations will explore several types of cancer, as well as the next frontier of health equity NEW BRUNSWICK, N.J., May 23, 2024 /PRNewswire/ -- Clinicians and scientists from Rutgers Cancer Institute and
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Zacks via Yahoo Finance· 3 days agoDr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such ...
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above Two Hundred Day Moving Average of $2.25
ETF DAILY NEWS· 5 days agoGalectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.25 and ...